SCHEMBL25857492

SCHEMBL25857492

CCOCOc1cc(C(F)(F)F)ccc1B(O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.42
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
ATM Q13315 1/20 0.42
CYP2C19 P33261 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
LIPE Q05469 1/20 0.36
MGLL Q99685 2/20 0.36
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
PDE2A O00408 1/20 0.34
GAA P10253 1/20 0.34
NPY1R P25929 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29953373 0.88 CYP2C19 (0.51) L3MBTL1MAPTLMNAATMCYP2C19
SCHEMBL15009911 0.88 CYP2C19 (0.51) L3MBTL1MAPTLMNAATMCYP2C19
SCHEMBL1042131 0.85 KDM4E (0.39) L3MBTL1MAPTLMNAATMCYP2C19
SCHEMBL30994957 0.85 KDM4E (0.39) L3MBTL1MAPTLMNAATMCYP2C19
SCHEMBL31197272 0.83 L3MBTL1 (0.43) L3MBTL1MAPTLMNAATMCYP2C19
SCHEMBL12244251 0.80 L3MBTL1 (0.44) L3MBTL1MAPTLMNAATMCYP2C19
SCHEMBL31314076 0.80 LIPE (0.36) L3MBTL1MAPTLMNACYP2C19CYP1A2
SCHEMBL28934573 0.79 L3MBTL1 (0.43) L3MBTL1MAPTLMNAATMCYP2C19
SCHEMBL12073388 0.78 L3MBTL1 (0.41) L3MBTL1MAPTLMNAATMCYP2C19
SCHEMBL29954889 0.76 ENPP2 (0.47) L3MBTL1MAPTCYP2C19CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119798221-A NLRP3 inflammation corpuscle inhibitor and application thereof 药捷安康(南京)科技股份有限公司 2025-04-11 CN disclosed
CN-119462517-A NLRP3 inflammation corpuscle inhibitor and application thereof 药捷安康(南京)科技股份有限公司 2025-02-18 CN disclosed
US-20240294542-A1 NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2024-09-05 US disclosed
WO-2023131277-A1 NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF 药捷安康(南京)科技股份有限公司 2023-07-13 WO disclosed
CN-116410140-A NLRP3 inflammation corpuscle inhibitor and application thereof 药捷安康(南京)科技股份有限公司 2023-07-11 CN disclosed
WO-2022253326-A1 NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF 药捷安康(南京)科技股份有限公司 2022-12-08 WO disclosed
CN-115433163-A NLRP3 inflammasome inhibitor and application thereof 药捷安康(南京)科技股份有限公司 2022-12-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294542-A1 NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF NLRP3, NLRP1, PYCARD L3MBTL1 3143/4885MAPT 57/4885LMNA 927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.